FDA
-
-
-
-
-
-
-
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
-
-
-
-
-
-
-
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
-
-
-
-
-
-
-
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Abeona Therapeutics (ABEO)
-
-
-
-
-
-
-
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
-
326,558 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

